In our Q--- Pharmaceutical Risk/Reward Index (RRI) Tanzania s score of --.- out of --- marks a slight worsening from its score last quarter of --.-, and lowers its position by one rank to --rd place out of -- countries analysed in the whole Middle East and Africa (MEA) region. A sizeable counterfeiting industry, poor healthcare funding, corruption, regulatory environment deficiencies and a number of other issues will conspire to keep Tanzania in a similarly lowly position in the MEA matrix. ...In our Q--- Pharmaceutical Risk/Reward Index (RRI) Tanzania s score of --.- out of --- marks a slight worsening from its score last quarter of --.-, and lowers its position by one rank to --rd place out of -- countries analysed in the whole Middle East and Africa (MEA) region. A sizeable counterfeiting industry, poor healthcare funding, corruption, regulatory environment deficiencies and a number of other issues will conspire to keep Tanzania in a similarly lowly position in the MEA matrix. In particular, issues relating to patent approvals and the regulatory system remain a major issue for foreign research-based pharmaceutical players. ...In particular, issues relating to patent approvals and the regulatory system remain a major issue for foreign research-based pharmaceutical players. Nevertheless, in comparison with many other African markets, Tanzania offers more commercial promise and a more stable overall business environment.
...The pharmaceuticals market in Tanzania is forecast to grow strongly over the next few years, largely due to an increasing disease burden. The government s interest in developing the pharmaceutical sector. High rate of population growth and urbanisation will continue to support pharmaceutical market growth, creating revenue earning opportunities for drugmakers. The government s interest in developing the pharmaceutical sector. ...Limited public healthcare provision and staff shortages. Many Tanzanians lack access to health facilities due to financial reasons or because of sparse healthcare infrastructure in rural areas.
...BMI View: Tanzania s pharmaceutical market will continue to suffer from a lack of domestic production as the majority of the country s medicine needs remain sourced from abroad. Despite government efforts to boost local pharmaceutical production, generic drugmakers, largely from India will dominate Tanzania s pharmaceutical landscape. ...BMI View: Tanzania s pharmaceutical market will continue to suffer from a lack of domestic production as the majority of the country s medicine needs remain sourced from abroad. Despite government efforts to boost local pharmaceutical production, generic drugmakers, largely from India will dominate Tanzania s pharmaceutical landscape. Moreover, supply chain issues will deter direct investment prospects by multinational drugmakers. ...